| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.56.7.843 |
| P698 | PubMed publication ID | 11294919 |
| P2093 | author name string | B Smith | |
| W Johnson | |||
| R J Barohn | |||
| G Parry | |||
| C Jackson | |||
| M Ross | |||
| R G Miller | |||
| E J Sorenson | |||
| R Mandler | |||
| A A Amato | |||
| M Mendoza | |||
| R Olney | |||
| D F Gelinas | |||
| P Bosch | |||
| M Graves | |||
| E Yuen | |||
| D H Moore | |||
| W Bryan | |||
| H Neville | |||
| S Ringel | |||
| P Kelkar | |||
| V Dronsky | |||
| J Petajan | |||
| M Bromberg | |||
| J Ravits | |||
| Western ALS Study Group | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase III clinical trial | Q42824827 |
| amyotrophic lateral sclerosis | Q206901 | ||
| gabapentin | Q410352 | ||
| P304 | page(s) | 843-848 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis | |
| P478 | volume | 56 |
| Q44478465 | A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters |
| Q35162749 | A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. |
| Q40679797 | A placebo-controlled trial of gabapentin in spinal muscular atrophy |
| Q38103571 | ALS Untangled No. 20: the Deanna protocol |
| Q37329513 | ALS drug development: reflections from the past and a way forward |
| Q36022219 | Advances in clinical trials for amyotrophic lateral sclerosis |
| Q37590212 | Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever |
| Q30455100 | Amyotrophic lateral sclerosis and palliative care: where we are, and the road ahead |
| Q36202825 | Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole |
| Q34004742 | Amyotrophic lateral sclerosis. |
| Q35048032 | Amyotrophic lateral sclerosis: progress and prospects for treatment |
| Q35014529 | Arimoclomol: a potential therapy under development for ALS. |
| Q36075065 | Assessment of disease progression in motor neuron disease |
| Q48426939 | Axotomy induces contrasting changes in calcium and calcium-binding proteins in oculomotor and hypoglossal nuclei of Balb/c mice |
| Q45173088 | Benefit of valproic acid in suppressing disease progression of ALS model mice |
| Q38646588 | Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. |
| Q57261217 | Chapter 14 Familial amyotrophic lateral sclerosis |
| Q35501852 | Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis |
| Q37513013 | Clinical outcome measures in spinal muscular atrophy |
| Q22305679 | Clinical significance in the change of decline in ALSFRS-R |
| Q36327410 | Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements |
| Q36565680 | Clinical trials in ALS: what did we learn from recent trials in humans? |
| Q36314443 | Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future |
| Q58125457 | Commentary on ‘A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS’ |
| Q42685032 | Current and emerging treatments for amyotrophic lateral sclerosis |
| Q59544338 | Current and potential therapeutics in motor neuron diseases |
| Q37981224 | Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis |
| Q36904850 | Current clinical trials in amyotrophic lateral sclerosis |
| Q24202239 | Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease |
| Q24242629 | Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease |
| Q24200270 | Drug treatment for spinal muscular atrophy types II and III |
| Q24234414 | Drug treatment for spinal muscular atrophy types II and III |
| Q24241759 | Drug treatment for spinal muscular atrophy types II and III |
| Q34584573 | Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. |
| Q36866600 | Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis |
| Q37909351 | Emerging drugs for amyotrophic lateral sclerosis |
| Q37867784 | Emerging targets and treatments in amyotrophic lateral sclerosis |
| Q58287999 | Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial |
| Q36565667 | Excitotoxicity and amyotrophic lateral sclerosis. |
| Q34982258 | From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials |
| Q34741619 | GNX-4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis |
| Q45025723 | Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease |
| Q24244456 | Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease |
| Q30239103 | Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease. |
| Q34401653 | Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research |
| Q37938694 | How can we improve clinical trials in amyotrophic lateral sclerosis? |
| Q38653220 | Inhibitory dysfunction in amyotrophic lateral sclerosis: future therapeutic opportunities |
| Q48377420 | Integrated molecular landscape of amyotrophic lateral sclerosis provides insights into disease etiology. |
| Q36679757 | Intraspinal stem cell transplantation for amyotrophic lateral sclerosis |
| Q42838813 | MRI predictors of long-term evolution in amyotrophic lateral sclerosis. |
| Q37384907 | Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life |
| Q36045308 | Measures and markers in amyotrophic lateral sclerosis |
| Q41158540 | Motor Alterations Induced by Chronic 4-Aminopyridine Infusion in the Spinal Cord In vivo: Role of Glutamate and GABA Receptors |
| Q37656842 | Motor neuron disease: systematic reviews of treatment for ALS and SMA. |
| Q38352222 | Neurogenic muscle cramps |
| Q62785679 | Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis |
| Q38736906 | Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials |
| Q35847073 | Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial |
| Q46343764 | Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease |
| Q35730907 | Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial |
| Q38933657 | Overstimulation of the inhibitory nervous system plays a role in the pathogenesis of neuromuscular and neurological diseases: a novel hypothesis. |
| Q39037807 | Pain in amyotrophic lateral sclerosis |
| Q44807720 | Physiopathology of ALS: therapeutic approach |
| Q36615226 | Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease |
| Q35007618 | Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the Am |
| Q36565682 | Preclinical trials--an update on translational research in ALS. |
| Q46612563 | Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole |
| Q52980048 | Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. |
| Q27338320 | Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis |
| Q46412061 | Sequential designs for clinical trials in amyotrophic lateral sclerosis |
| Q35051773 | Small molecule glutaminase inhibitors block glutamate release from stimulated microglia |
| Q51312456 | Spirometer-dependence of vital capacity in ALS: validation of a portable device in 52 patients. |
| Q51852192 | Stratifying disease stages with different progression rates determined by electrophysiological tests in patients with amyotrophic lateral sclerosis. |
| Q49905442 | Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD. |
| Q57911703 | The El Escorial criteria: Strengths and weaknesses |
| Q33339275 | The Wobbler Mouse: A Neurodegeneration Jigsaw Puzzle |
| Q89645812 | The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future |
| Q46977869 | The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS). |
| Q38892540 | Therapeutic approach to pain in neurodegenerative diseases: current evidence and perspectives. |
| Q34974850 | Therapeutic developments in the treatment of amyotrophic lateral sclerosis |
| Q37198692 | Therapy development for ALS: lessons learned and path forward |
| Q36014761 | Therapy development for spinal muscular atrophy in SMN independent targets. |
| Q58125301 | Thrombopoietin is ineffective in a mouse model of motor neuron disease |
| Q24200285 | Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease |
| Q24250095 | Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease |
| Q24241570 | Treatment for familial amyotrophic lateral sclerosis/motor neuron disease |
| Q24245711 | Treatment for familial amyotrophic lateral sclerosis/motor neuron disease |
| Q38188662 | Why is ALS so Difficult to Treat? |
| Q54315826 | [Functional rating scales for amyotrophic lateral sclerosis] |
| Q76378542 | [Molecular mechanisms of amyotrophic lateral sclerosis: recent contributions from studies in animal models] |
Search more.